Fosun Pharma’s Subsidiary Gains Approval for New Drug Luvometinib

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, has received approval from the National Medical Products Administration for the drug registration of Luvometinib Tablets. This new drug is intended for the treatment of adult patients with Langerhans cell histiocytosis and histiocytic neoplasms, as well as pediatric patients aged 2 years and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely resected. This approval marks a significant step in Fosun Pharma’s efforts to expand its portfolio of innovative treatments and strengthen its position in the pharmaceutical industry.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in the People’s Republic of China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, with a market emphasis on innovative drugs and healthcare services.

Average Trading Volume: 4,628,611

Technical Sentiment Signal: Hold

Current Market Cap: HK$62.5B

For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.